Hepatitis C virus E1 glycoprotein (HCV E1) (HCV E1)

The Hepatitis C virus (HCV) E1 glycoprotein is a critical structural component of the viral envelope, functioning as a type I transmembrane protein that forms a non-covalent heterodimer with the E2 glycoprotein [1, 5]. This E1/E2 complex is essential for the virus's ability to attach to and enter host hepatocytes, with E1 specifically implicated in the fusion of the viral envelope with the host endosomal membrane [2, 3]. Recent structural studies suggest that E1 may act as the primary fusion protein or work cooperatively with E2 in a novel fusion mechanism distinct from other Flaviviridae [3, 12]. Beyond entry, E1 plays roles in viral assembly, genome encapsidation, and the association of the virus with host lipoproteins, which facilitates immune evasion [3, 8]. While most current direct-acting antivirals target non-structural proteins like NS3 or NS5A, E1 is a primary target for the development of prophylactic vaccines and neutralizing monoclonal antibodies [4, 15]. Monoclonal antibodies such as H-111 specifically target E1 to block viral attachment and infectivity [11]. Additionally, host-targeting agents like Celgosivir interfere with E1 folding by inhibiting alpha-glucosidase, thereby reducing viral production [14]. Therapeutic strategies focusing on E1 aim to block the earliest stages of infection, offering a high barrier to resistance compared to traditional antivirals [2, 13].

Other names

Envelope glycoprotein E1E1 proteingp35HCV E1

Inhibition of viral entry and membrane fusion through neutralization of the E1 glycoprotein, disruption of E1/E2 heterodimerization, or interference with glycoprotein folding and glycosylation [2, 14].